Table 5

 Summary of x ray scores for infliximab and etanercept groups at baseline through week 14

EvaluationWeeknInfliximabEtanercept
Mean (SD)MediannMean (SD)Median
JSN, joint space narrowing; SHS, Sharp score with the van der Heijde modification.
*Sample size variations between weeks 0 and 14 affected the numerical differences observed.
SHS
Week 01332.5 (39.7)20.51447.5 (50.8)26.6
Week 141236.2 (40.6)21.01252.2 (53.6)33.3
*Change from week 0 to 14121.0 (4.0)0.0120.4 (1.3)0.3
Total erosions
Week 01318.7 (18.6)18.01428.8 (32.2)15.2
Week 141220.4 (18.5)18.81231.3 (34.0)17.8
*Change from week 0 to 14120.1 (0.84)0.012−0.1 (0.65)0.0
JSN
Week 01313.8 (22.0)7.51418.7 (19.5)12.6
Week 141215.8 (23.1)8.01220.9 (20.7)16.0
*Change from week 0 to 14120.9 (3.39)0.0120.6 (1.17)0.0